Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 815Uterine Cervical Neoplasms 549Endometrial Neoplasms 467Breast Neoplasms 227Fallopian Tube Neoplasms 202Colorectal Neoplasms 182Carcinoma, Non-Small-Cell Lung 163Neoplasms 140Stomach Neoplasms 128Pancreatic Neoplasms 120Prostatic Neoplasms 109Melanoma 108Neoplasm Metastasis 107Lung Neoplasms 105Carcinoma, Ovarian Epithelial 94Triple Negative Breast Neoplasms 92Squamous Cell Carcinoma of Head and Neck 82Esophageal Neoplasms 78Head and Neck Neoplasms 77Carcinoma, Renal Cell 76Urinary Bladder Neoplasms 75Uterine Neoplasms 68Vulvar Neoplasms 66Colonic Neoplasms 60Uterine Cervical Dysplasia 59Peritoneal Neoplasms 59Carcinoma, Hepatocellular 59Sarcoma 53Carcinoma, Transitional Cell 49Papillomavirus Infections 47

Interventions

Specimen Handling 1Biopsy 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Serous Adenocarcinoma × Gynecologic × 1 year × Clear all
NCT04494113 2026-05-13

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Active not recruiting
12 enrolled
Gynecologic

Endometrial Serous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡